Crossmark

Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Crossref DOI link: https://doi.org/10.1016/j.eclinm.2023.101826

Published Print: 2023-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Sofen, Howard https://orcid.org/0000-0001-7789-6915
Bissonnette, Robert

Yosipovitch, Gil

Silverberg, Jonathan I.

Tyring, Stephen

Loo, Wei Jing

Zook, Matthew

Lee, Mark

Zou, Liangxing

Jiang, Guang-Liang

Paolini, John F.
Funding

Funding for this research was provided by:

Kiniksa Pharmaceuticals
License Information

Text and Data Mining valid from 2023-03-01

Text and Data Mining valid from 2023-03-01

Version of Record valid from 2023-01-06
More Information

This article is maintained by: Elsevier

Article Title: Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Journal Title: eClinicalMedicine

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eclinm.2023.101826

Content Type: article

Copyright: © 2023 The Author(s). Published by Elsevier Ltd.

Document is current

Any future updates will be listed below